News

GEN - Genetic Engineering and Biotechnology News1h
The Body’s Delta Force: Natural Killer Cells Re-Emerge
Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and autoimmunity.
PharmExec2h
Merida Biosciences Launches with $121 Million in Series A Financing to Develop Precision Therapeutics for Autoimmune, Allergic Diseases
Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...
AlphaGalileo11h
Biomimetic Synthesis of Natural Products: Progress, Challenges and Prospects
A new study published in Engineering explores the biomimetic synthesis of natural products. This research, led by scientists ...
Becker's Hospital Review1d
After patient’s death, study cites potential barrier to Elevidys
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...
Zacks Research Issues Optimistic Outlook for NKTR Earnings
Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...
GEN - Genetic Engineering and Biotechnology News2d
Combining Engineering and Biology to Drive More “Cultured” Therapies
Bioprocessing has always been a bit late in adopting the latest engineering techniques, e.g., computational fluid dynamics to ...
What is Zacks Research’s Estimate for NKTR Q1 Earnings?
Stock analysts at Zacks Research issued their Q1 2027 earnings estimates for Nektar Therapeutics in a research report issued on Wednesday, April 2nd. Zacks Research analyst K. Das forecasts that the ...